Is it appropriate to prescribe 120 mg of Arcoxia (etoricoxib) to a 17‑year‑old patient?

Arcoxia 120mg Should NOT Be Prescribed to a 17-Year-Old

Etoricoxib (Arcoxia) is contraindicated in patients under 18 years of age according to FDA labeling, which explicitly states "Children under 18 years of age: Ask a doctor" for any use 1. This represents a clear age restriction that precludes prescribing the 120 mg dose to a 17-year-old patient.

Age-Based Contraindication

The FDA drug label for Arcoxia establishes 18 years as the minimum age for use 1. While the label text provided appears to reference a homeopathic formulation (based on the sublingual dosing instructions), the age restriction of 18 years remains the critical regulatory guidance. A 17-year-old patient falls below this threshold by definition.

Limited Pediatric Evidence

The available research evidence does not support routine use of etoricoxib 120 mg in adolescents:

• One retrospective study examined etoricoxib tolerance in children with NSAID hypersensitivity (mean age 13.5 years), but this addressed drug allergy testing rather than routine pain management 2
• A dental surgery study included patients "aged ≥16 years," establishing 120 mg as the minimum dose for maximal efficacy in acute pain, but this was conducted in a population that included adults 3
• No high-quality evidence specifically evaluates the safety, efficacy, or appropriate dosing of etoricoxib 120 mg in the 16-17 year age group for standard indications

Cardiovascular Concerns in Any Age Group

Even if age were not a barrier, etoricoxib carries significant cardiovascular risks that warrant caution:

• Etoricoxib and diclofenac have similar COX-2 selectivity profiles and associated thrombotic event risks 4
• The American Heart Association scientific statement notes that etoricoxib "would not be among the first choices for pain relief with regard to safety, especially in individuals with or at risk for cardiovascular disease" 4
• The high degree of COX-2 selectivity places etoricoxib at the higher-risk end of the NSAID spectrum for cardiovascular events 4

Clinical Recommendation

For a 17-year-old requiring analgesia, use age-appropriate alternatives:

• Acetaminophen as first-line for mild-to-moderate pain
• Ibuprofen (standard NSAID with established pediatric dosing) for inflammatory pain
• Naproxen if longer duration of action is needed
• Consider non-pharmacological approaches (physical therapy, ice/heat) as adjuncts

The 120 mg dose of etoricoxib is particularly inappropriate given it represents the higher end of the dosing spectrum designed for severe acute pain or chronic inflammatory conditions in adults 3, 5.

Key Pitfall to Avoid

Do not extrapolate adult dosing to adolescents approaching age 18. The regulatory age cutoff exists because pharmacokinetic, pharmacodynamic, and safety data in pediatric populations are insufficient. Wait until the patient turns 18 before considering etoricoxib, and even then, evaluate cardiovascular risk factors and consider safer alternatives first 4.